Medical imaging — neural visualisation

Independent CRO

Clinical trials where
imaging defines
the outcome.

Berlin  ·  Philadelphia  ·  Est. 2006

Imaging core lab, full CRO management, and consulting — across therapeutic areas and all development phases.

For twenty years, we have been the team sponsors call when imaging is not a secondary endpoint — but the reason the study exists.
Clinical trial management — data-driven oversight
01
CRO Services

Full trial management, imaging integrated from day one.

Imaging protocol, site qualification, DICOM logistics, and independent reads are managed by the same team running your trial — not contracted out to a separate imaging vendor. Most sponsors coordinate a CRO and an imaging core lab independently. We are both — one team, one point of accountability, from protocol to final read.

  • Protocol development
  • Site selection & qualification
  • Regulatory affairs — FDA, EMA, national
  • Clinical monitoring (CRA services)
  • Data management & eCRF
  • Safety & pharmacovigilance
Full capabilities
Independent image read — radiologist at workstation
02
Imaging Core Lab

Independent management of imaging in your trial.

From imaging charter and site qualification through DICOM image collection, quality control, and blinded reads to the final results dataset — we manage every imaging step with the rigour that regulatory submissions demand. Response criteria covered include RECIST 1.1, iRECIST, PERCIST, and study-specific frameworks.

  • Imaging Charter development
  • Site qualification for imaging
  • DICOM collection, transfer & QC
  • Independent blinded reads — RECIST, iRECIST, PERCIST
  • Dosimetry — diagnostic & therapeutic radiopharmaceuticals
  • Adjudication & expert panel assessments
  • Reader training & management
  • Statistical analysis & reporting
Full capabilities
Scientific consulting — collaborative planning
03
Consulting

Strategic advice for sponsors who take imaging seriously.

Two decades of direct experience in imaging-based trials across therapeutic areas and development phases. We help sponsors design programs that satisfy regulatory expectations and prepare for productive interactions with FDA and EMA.

  • Regulatory meeting preparation & support
  • Imaging endpoint strategy
  • Clinical development program design
  • Radioligand therapy program support
  • Due diligence
  • Expert panel organisation
Full capabilities

When a programme requires expertise beyond imaging — biostatistics, regulatory writing, toxicology, CMC — pharmtrace works through CONELIS, a Berlin-based network of independent experts in pharmaceutical development. Members can be engaged individually or assembled as interdisciplinary teams, on demand, without the overhead of a large organisation. conelis.org ↗

Radiopharmaceuticals Oncology Radioligand Therapy Neurology Cardiology Medical Devices First-in-Human Phase 1 – 4 Marketing Authorisation
ERICA imaging platform — study management interface
Our Platform

ERICA — built for clinical imaging.

ERICA is our proprietary, fully validated imaging platform — purpose-built for the demands of clinical trials. It covers DICOM image storage, technical and medical quality control, and independent blinded reads in a single, regulatory-compliant environment.

Every project-specific configuration is separately validated. No general-purpose software adapted for clinical use — a system designed from the ground up for this work.

GAMP5 Category 5 — full custom application validation
FDA 21 CFR Part 11 — electronic records & signatures
ICH-GCP & ISO 14155 — pharmaceutical & device trials
Per-study configuration validation — no blanket approvals
20

Twenty years. Independent. Private.
Committed to the work.

Twenty years of imaging trials teaches you exactly where they break — and how to prevent it.

Berlin · Philadelphia · Est. 2006

Where we work

Berlin and Philadelphia.
Active across four continents.

pharmtrace manages clinical trials globally from two offices that work as one team — with direct access to local expertise where it matters, and clear accountability at every step.

pharmtrace global reach — clinical trials across Europe, North America, Asia and Australasia
Europe Most European countries, including Switzerland and the UK — under EMA and national regulatory frameworks.
North America United States and Canada, under FDA and Health Canada regulatory frameworks.
Asia Japan, China, and Vietnam — under PMDA, NMPA, and national regulatory frameworks.
Australasia Australia and New Zealand, under TGA and Medsafe — regulatory environments often used for early-phase and first-in-human radiopharmaceutical studies.

Germany

Berlin

Wolframstrasse 93–94
12105 Berlin

United States

Philadelphia, PA

One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103